ReviewCurrent aging science2026
Frontotemporal Dementia, Current Diagnosis and Treatment Emphasis on Natural Products: A Review.
Review in Current aging science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFrontotemporal dementia (FTD) refers to a spectrum of brain illnesses that mostly affects the frontal and temporal lobes. These regions are commonly related to personality, behaviour, and communication. It is brought on by aberrant protein aggregates, genetics and mutation. FTD most frequently affect people between the ages of 45 and 65 but can also affect young and elderly people. It is estimated that 1.0 to 15.4 per 100,000 members of the population can be affected by FTD in the near future. About 20,000 to 30,000 cases of FTD were reported in the USA alone in 2016. Presently, no specific pharmaceutical treatments for FTD have been authorized by the US Food and Drug Administration.
methodsThe present review demonstrates the risk factors, pathogenesis, pathophysiology, diagnostic criteria and treatment of FTD using a number of synthetic and natural drugs to treat the disease and focuses on natural products used to manage the disease. The literature search was done by online databases of SciFinder, Medline, Pubmed, GoogleScholar and Scopus.
resultsVarious pharmacological and non-pharmacological interventions have been recorded to treat the disease. Primary treatment is a temporary reduction in the symptoms and progression of the disease. Curcumin, glycyrrhiza, Quercetin, Bacopa monnieri, Panax ginseng, galantamine and many more are recorded for this activity. DISCUSSION: Herbal remedies and Phytoconstituents, either alone or in combination, could serve as excellent therapies for dementia with fewer adverse effects. Anticholinesterase, anti-inflammatory, antioxidant compounds are gaining interest in the management of FTD.
conclusionHerbal extract and compounds are helpful in management of the disease with their specific mode of action.
Indexed as
Identifiers
40114569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.